Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status

Arcturus Therapeutics ARCT announced that the FDA has granted an orphan drug designation to its pipeline candidate, ARCT-810, for the treatment of ornithine transcarbamylase deficiency (“OTCD”), an inherited metabolic disorder. OTCD is the most common urea cycle disorder, which impacts an individual’s ability to remove toxic waste products from the body.

ARCT-810 is a RNA-based pre-clinical candidate, which has been designed using the company’s proprietary LUNAR lipid-mediated delivery platform. The company is planning to submit an investigational new drug application to the FDA in early 2020 to initiate clinical study on ARCT-810.

Notably, the orphan drug designation is granted to drugs capable of treating rare diseases that affect less than 200,000 people in the United States. The designation also makes a company entitled to certain other benefits including tax credits related to clinical trial expenses and exemption from the FDA user fee.

The status makes ARCT-810 eligible for seven years of marketing exclusivity in the United States.

Apart from OTCD, the company has collaborated with Cystic Fibrosis Foundation for developing RNA-based therapy to treat cystic fibrosis.

Arcturus’ shares have rallied 108.4% so far this year compared with the industry’s increase of 5.4%.

Multiple pharma/biotechs have signed collaborations with Arcturus to use its RNA-based technology to develop treatments that target different indications.

Last month, the company expanded its existing collaboration with Ultragenyx Pharmaceutical RARE to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets. Pursuant to the agreement, Ultragenx will pay $30 million of upfront payments to Arcturus, including $6 million cash for collaboration agreement amendment and $24 million equity investment at $10 per share. Arcturus is also entitled to preclinical, clinical, regulatory and sales milestone payments for each product developed under the collaboration. With the agreement, Ultragenyx is now Arcturus’ largest shareholder. Ultragenyx has an option to purchase an additional 600,000 shares of Arcturus’ common stock at $16 per share.

Arcturus has an agreement with Takeda Pharmaceutical TAK for the development of therapies targeting nonalcoholic steatohepatitis and with J&J JNJ for the treatment of hepatitis B.

The company completed the change of its domicile from Israel to Delaware last month.

Arcturus Therapeutics Holdings Inc. Price

 

Arcturus Therapeutics Holdings Inc. Price

Arcturus Therapeutics Holdings Inc. price | Alcobra Ltd. Quote

Zacks Rank

Arcturus currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Johnson & Johnson (JNJ) : Free Stock Analysis Report
 
Ultragenyx Pharmaceutical Inc. (RARE) : Free Stock Analysis Report
 
Alcobra Ltd. (ARCT) : Free Stock Analysis Report
 
Takeda Pharmaceutical Co. (TAK) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research